High-dose gamma globulin plus dipyridamole for Kawasaki disease in children: An investigation of therapeutic effectiveness

The therapeutic efficacy of high-dose (HD) gamma globulin (GG) co-administered with dipyridamole (DIP) was assessed in children with Kawasaki disease (KD). Among 100 enrolled pediatric KD cases, the control group was treated with low-dose (LD)-GG, while the research group received HD-GG. Both groups also underwent standard therapy and oral DIP. Statistical comparisons were conducted for overall effectiveness, safety, coronary artery diameter grading, symptom resolution timelines and serum markers of inflammation. Results indicated the research group achieved higher therapeutic effectiveness than controls while maintaining similar safety profiles. Additionally, the research group exhibited superior coronary artery diameter grading, quicker symptomatic relief and more robust anti-inflammatory effects as measured by serum biomarkers. Conclusively, for pediatric KD, HD-GG+DIP achieves robust therapeutic outcomes while maintaining a safe side-effect profile. Improvements in coronary artery diameter grading, faster symptom relief and regulated serum inflammatory cytokine levels further support its broader clinical application.